Clinical Trials
Study Title:
Phase 3 Trial Using the SYK inhibitor, Entospletinib, in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, NPM1 Mutated Acute Myelogenous Leukemia
|
For more information about the trial above please contact the study team:
|